APP and Alzheimer disease: As a proof‐of‐concept strategy, we targeted the β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1), which is a key component in amyloid beta peptide (Aβ) production in AD (Vassar et al, 1999; Cai et al, 2001).